Cambio - Excellence in Molecular Biology

Oligo Synthesis

Oligo Synthesis : CEPs

Prices quoted are for single packs only. For multiples of the same product please request a quote. Some of Glen's products are hazardous and may be subject to additional shipping charges. Full product information is available on Glen Research's website.

dDss-CE Phosphoramidite

dDss-CE Phosphoramidite

Glen Research

Structure

Catalog Number: 10-1524-xx

Description: dDss-CE Phosphoramidite

5'-O-(4,4'-Dimethoxytrityl)-1'-(6-(2,2'-bithiophen-5-yl)-
1-deazapurin-9-yl)-2'-deoxy-Β-D-ribofuranosyl-
3'-[(2-cyanoethyl)-(N,N-diisopropyl)]phosphoramidite
Formula: C49H52N5O6PS2 M.W.: 902.07 F.W.: 461.451

Diluent: Anhydrous Acetonitrile
Coupling: No changes needed from standard method recommended by synthesizer manufacturer.
Deprotection: No changes needed from standard method recommended by synthesizer manufacturer.
Storage: Freezer storage, -10 to -30°C, dry
Stability in Solution: 1-2 days
Please Note: This product is covered by patents or patents pending owned by TagCyx Biotechnologies. Purchase of this product includes a limited license to use this product solely for research. This license specifically excludes: (a) therapeutic or diagnostic applications (including products or services that incorporate this product), (b) any in vivo toxicity/safety study in support of an investigational new drug application (or foreign counterpart), (c) resale, or (d) gene functionalization activities (including products or services that incorporate data derived from gene functionalization activities) if such activities have commercial application. All of the above require a separate license from TagCyx Biotechnologies. Neither this product nor any product created through its use may be used in human clinical trials.

Unnatural base pairs display unique abilities in duplex DNA and in nucleic acid and protein biosyntheses. A standard Watson and Crick base pair is formed between iso-C and iso-G, but the hydrogen bonding pattern is quite different from the natural base pairs A-T and C-G. (The 5-methyl analogue was chosen as the synthetic target due to the reported instability of 2’-deoxyisocytidine caused by deamination during oligonucleotide synthesis or deprotection.)

The unnatural base pair between 7-(2-thienyl)-imidazo[4,5-b]pyridine (Ds) and pyrrole-2-carbaldehyde (Pa) is formed by specific hydrophobic shape complementation. The shape of the Ds-Pa pair is different from those of the natural A-T and G-C pairs, but the Ds-Pa pair works together with the natural pairs in in vitro replication and transcription. Pa also functions as a template base for incorporating another unnatural base, 2-amino-6-(2-thienyl)purine (s), into RNA. The s base also acts as a unique fluorescent base analog in DNA and RNA fragments. dDss is strongly fluorescent and is useful as a fluorescent tag for DNA detection. dDss also forms a base pair with dPa. Biotin PaTP can be site-specifically incorporated into RNA, opposite dDs at a desired position in DNA templates, by T7 transcription. Similarly, the fluorescent s base can be site-specifically incorporated into RNA opposite dPa in DNA templates.

dDss-CE Phosphoramidite

INTELLECTUAL PROPERTY: This product is covered by patents or patents pending owned by TagCyx Biotechnologies.  Purchase of this product includes a limited licence to use this product soley for research.  This licence specifically excludes

  1. therapeutic or diagnostic applications (including products or services that incorporate this product)
  2. any in vivo toxicity/safety study in support of an investigational new drug application (or foreign counterpart)
  3. resale
  4. gene functionalisation activities (including products or services that incorporate data derived from gene functionalisation activities) if such activities have commercial application.

All of the above require a separate licence from TagCyx Biotechnologies.  Neither this product nor any product created through its use may be used in human clinical trials.

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

dDss-CE Phosphoramidite

dDss-CE Phosphoramidite

Glen Research

MSDS

Glen Report 23.1: Product Update - Unnatural Base Pairs

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

dDss-CE Phosphoramidite

dDss-CE Phosphoramidite

Glen Research

  1. I Hirao, et al, Nucleic Acids symp Ser (Oxf), 2006, 33-4
  2. T Mitsui, M Kimoto, R Kawai, S Yokoyama and I Hirao, Tetrahedron, 2007, 35, 3528-3537
  3. M Kimoto, T Mitsui, S Yokoyama and I Hirao, J Am Chem Soc, 2010, 132, 4988-4988
  4. K Moriyama, M Kimoto, T Mitsui, S Yokoyama and I Hirao, Nucl Acids Res, 2005, 33 e129
  5. Y Hikida, M Kimoto, S Yokoyama and I Hirao, Nat Protoc, 2010, 5, 1312-23
  6. M Kimoto, R S Cox, I Hirao, Expert Rev Mol Diagn, 2011, 11, 321-31

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

dDss-CE Phosphoramidite

dDss-CE Phosphoramidite

Glen Research

INTELLECTUAL PROPERTY: This product is covered by patents or patents pending owned by TagCyx Biotechnologies.  Purchase of this product includes a limited licence to use this product soley for research.  This licence specifically excludes

  1. therapeutic or diagnostic applications (including products or services that incorporate this product)
  2. any in vivo toxicity/safety study in support of an investigational new drug application (or foreign counterpart)
  3. resale
  4. gene functionalisation activities (including products or services that incorporate data derived from gene functionalisation activities) if such activities have commercial application.

All of the above require a separate licence from TagCyx Biotechnologies.  Neither this product nor any product created through its use may be used in human clinical trials.

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

dDss-CE Phosphoramidite

dDss-CE Phosphoramidite

Glen Research

DILUTION/COUPLING DATA

The table below shows pack size data and, for solutions, dilutions and approximate couplings based on normal priming procedures. Please link for more detailed usage information with the various synthesizers.

ABI 392/394
Cat.No. Pack
Size
Grams/
Pack
0.1M Dil.
(mL)
LV40 LV200 40nm 0.2µm 1µm 10µm
Approximate Number of Additions
10-1524-02 0.25grams .25grams 2.77 79 47.4 29.63 21.55 15.8 3.95
10-1524-90 100µmoles .09grams 1 20 12 7.5 5.45 4 1
10-1524-95 50µmoles .045grams .5 3.33 2 1.25 .91 .67 .17
Expedite
Cat.No. Pack
Size
Grams/
Pack
Dilution
(mL)
Molarity 50nm 0.2µm 1µm 15µm
Approximate Number of Additions
10-1524-02 0.25grams .25grams 4.14 .07 76.4 47.75 34.73 4.78
10-1524-90 100µmoles .09grams 1.5 .07 23.6 14.75 10.73 1.48
10-1524-95 50µmoles .045grams .75 .07 8.6 5.38 3.91 .54
Beckman
Cat.No. Pack
Size
Grams/
Pack
Dilution
(mL)
Molarity 30nm 200nm 1000nm

Approximate Number of Additions
10-1524-02 0.25grams .25grams 4.14 .07 78 48.75 35.45

10-1524-90 100µmoles .09grams 1.5 .07 25.2 15.75 11.45

10-1524-95 50µmoles .045grams .75 .07 10.2 6.38 4.64

 

INTELLECTUAL PROPERTY: This product is covered by patents or patents pending owned by TagCyx Biotechnologies.  Purchase of this product includes a limited licence to use this product soley for research.  This licence specifically excludes

  1. therapeutic or diagnostic applications (including products or services that incorporate this product)
  2. any in vivo toxicity/safety study in support of an investigational new drug application (or foreign counterpart)
  3. resale
  4. gene functionalisation activities (including products or services that incorporate data derived from gene functionalisation activities) if such activities have commercial application.

All of the above require a separate licence from TagCyx Biotechnologies.  Neither this product nor any product created through its use may be used in human clinical trials.

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200